My previous cautious thesis for Novo Nordisk ( NVO ) appears to have aged well; the stock has dropped by more than 50% since last July, and is now, in my opinion, far too cheap to ignore. Add in some impressive fundamentals—an 18% increase inI am a highly experienced Chief Financial Officer (CFO) with a strong background in the oilfield and real estate industries. With over a decade of experience in finance, I have led numerous complex due diligence efforts and M&A transactions, both domestically and intern ...